We read with great interest the recent article by Dr Stühlinger et al 1 dealing with the relationship among asymmetric dimethylarginine (ADMA), homocyst(e)ine, and endothelial function in young healthy adults, patients with peripheral arterial disease, and older healthy adults. The results of their study demonstrated that experimentally induced hyperhomocyst(e)inemia increased plasma ADMA, an effect that was temporally related to a decline in endothelial vasodilator function. Dr Stühlinger et al 1 proposed that ADMA might have a causal role in endothelial dysfunction because there was a significant inverse correlation between plasma ADMA and flow-mediated dilatation of the brachial artery.
Response
We thank Drs Tsuda and Nishio for their interesting observations related to asymmetric dimethylarginine (ADMA) and estrogen. Estrogen therapy for postmenopausal women is known to improve endothelial vasodilator function. 1 The beneficial effect of estrogen on the endothelium has been attributed to its antioxidant properties and to its effect on transcription of NO synthase. Of course, we are intrigued by the observation that estrogen also reduces plasma levels of the endogenous NO synthase inhibitor ADMA, 2 which is consistent with the finding that estrogen increases the degradation of ADMA by dimethylarginine dimethylaminohydrolase (DDAH). 3 Estrogen joins several other drugs that recently have been shown to improve endothelial function and to reduce plasma ADMA levels, including thiazolidinediones, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, and metformin.
We speculate that the effect of these agents to reduce ADMA is related to a property shared by each agent, ie, the capacity to ameliorate endothelial oxidative stress. Elevated levels of angiotensin II and glucose are known to increase vascular generation of oxygen-derived free radicals. Pharmacological antagonism of angiotensin II blocks its effect to increase the activity and expression in the vessel wall of the oxidative enzyme NAD(P)H oxygenase. Agents that enhance insulin sensitivity may also ameliorate oxidative stress. By doing so, these agents preserve the ability of DDAH to metabolize ADMA. Under conditions of oxidative stress, DDAH activity is impaired, and ADMA accumulates. 4 Our data, and those of others, indicate that this is an important mechanism for the endothelial vasodilator dysfunction that occurs in hyperhomocysteinemia 5 and in other metabolic perturbations.
Our study was not designed to examine the effect of gender on the response to methionine challenge. That being said, a reanalysis of the data revealed the possibility of an intriguing dissimilarity between men and women. Although there were no gender differences in plasma homocysteine or ADMA before or after oral methionine, and no gender difference in baseline flow-mediated vasodilation, flow-mediated vasodilation was reduced to a greater degree in male participants 4 hours after the methionine loading test compared with the postmenopausal female patients (2.0Ϯ1.3% versus 4.1Ϯ1.4%; Pϭ0.034). The postmenopausal patients were not using estrogen supplementation.
Accordingly, we agree with Drs Tsuda and Nishio that it would be of interest to conduct additional studies to delineate the interaction of gender differences or hormonal status on homocysteineinduced, ADMA-mediated endothelial vasodilator dysfunction.
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